BioStock: Cyxone looks forward to study start

Biopharmaceutical company Cyxone is fully focused on the upcoming phase IIb study with the candidate Rabeximod in rheumatoid arthritis. In the company's recently published interim report, acting CEO Carl-Magnus Högerkorp describes the preparatory work and updates on events in the company's pipeline. BioStock reached out to Högerkorp to find out more about the study and coming activities.

Read the interview with Cyxone's acting CEO Carl-Magnus Högerkorp at biostock.se:

https://www.biostock.se/en/2022/08/cyxone-looks-forward-to-study-start/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/